There is no question that diversity matters—it does. In the context of clinical trials, a lack of diverse representation can lead to medicines and vaccines that are less effective in treating disease and health conditions in groups underrepresented in such trials, giving rise to health equity concerns. The issue of health equity has become even more pressing in light of the recent COVID-19 pandemic.